tirzepatide cardiovascular outcome trial SURPASS-CVOT Published: Large Confirms CVD Efficacy of Comparative Cardiovascular Pharmacovigilance of Semaglutide

Pricing may vary

Comparing Zepbound's Doses Against Semaglutide The first head-to-head trial in obesity (SURMOUNT-5) compared the maximum tolerated dose of tirzepatide (10 or 15 mg) to the maximum tolerated dose of semaglutide (1.7 or 2.4 mg) over 72 weeks

This increased participation in active pursuits provides additional mental health benefits through exercise, nature exposure, and social connection

Severe headache, visual disturbances and pulsatile tinnitus are recognised features of raised ICP [5], however impairments in cognitive function are also well documented

The Ozempic label describes starting at a low weekly dose and stepping up to improve tolerance